{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:56:05Z","timestamp":1793220965391,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41574-023-00939-9","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T14:02:57Z","timestamp":1702562577000},"page":"75-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A pivotal year for NAFLD and NASH therapeutics"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8062-1346","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hep.28276","volume":"63","author":"JF Dufour","year":"2016","unstructured":"Dufour, J. F. Time to abandon NASH? Hepatology 63, 9\u201310 (2016).","journal-title":"Hepatology"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u201397.e10 (2015).","journal-title":"Gastroenterology"},{"key":"939_CR4","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat. Med. 29, 2656\u20132664 (2023).","journal-title":"Nat. Med."},{"key":"939_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","volume":"72","author":"F Ravaioli","year":"2023","unstructured":"Ravaioli, F. et al. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut 72, 1399\u20131409 (2023).","journal-title":"Gut"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE M\u00f3zes","year":"2023","unstructured":"M\u00f3zes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704\u2013713 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29, 2919\u20132928 (2023).","journal-title":"Nat. Med."},{"key":"939_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998\u20131008 (2023).","journal-title":"N. Engl. J. Med."},{"key":"939_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 8, 1080\u20131093 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"JF Dufour","year":"2020","unstructured":"Dufour, J. F., Caussy, C. & Loomba, R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 69, 1877\u20131884 (2020).","journal-title":"Gut"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00939-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T14:09:35Z","timestamp":1705500575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00939-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1038\/s41574-023-00939-9","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"14 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-F.D. declares the following competing interests: participation on advisory committees for Alentis, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Enyo, Esai, Genfit, Intercept, Inventiva, Ipsen, Lilly, Madrigal, Merck, Novartis, Novo-Nordisk and Roche. Speaking and teaching engagements for Astra-Zeneca, Bristol-Myers Squibb, Intercept, Ipsen and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}